1. Scientific and clinical relevance of non-cellular tumor microenvironment components in ovarian cancer chemotherapy resistance
   Marta Ostrowska-Lesko et al, 2024, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer CrossRef
2. Proton pump inhibitors display anti‐tumour potential in glioma
   Bihan Li et al, 2023, Cell Proliferation CrossRef
3. Epithelial Ovarian Cancer: Microenvironment and Immunecheck Point Inhibitors
   Zineb Kabala et al, 2023, European Journal of Medical and Health Sciences CrossRef
4. Lipopolysaccharide-Educated Cancer-Associated Fibroblasts Facilitate Malignant Progression of Ovarian Cancer Cells via the NF-kB/IL-6/JAK2 Signal Transduction
   Dongjie Wang et al, 2024, Molecular Biotechnology CrossRef
5. STING inhibitors sensitize platinum chemotherapy in ovarian cancer by inhibiting the CGAS-STING pathway in cancer-associated fibroblasts (CAFs)
   Jiale Liu et al, 2024, Cancer Letters CrossRef
6. Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on drug response genes to predict prognosis and therapeutic response in ovarian cancer
   ZhenWei Zhang et al, 2024, Heliyon CrossRef
7. Secreted Soluble Factors from Tumor-Activated Mesenchymal Stromal Cells Confer Platinum Chemoresistance to Ovarian Cancer Cells
   Yifat Koren Carmi et al, 2023, International Journal of Molecular Sciences CrossRef
8. Long noncoding RNAs as therapeutic targets to overcome chemoresistance in ovarian cancer
   Linjiao Chen et al, 2022, Frontiers in Cell and Developmental Biology CrossRef
9. Advances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters
   Andaleeb Sajid et al, 2023, Nature Reviews Cancer CrossRef
10. Expression of human dCTP pyrophosphatase 1 (DCTPP1) and its association with cisplatin resistance characteristics in ovarian cancer
    Yu Wang et al, 2024, Journal of Cellular and Molecular Medicine CrossRef